Paclitaxel-carboplation in advanced ovarian cancer

ABSTRACT

This study included 85 female patients with advanced ovarian epithelial cancer. Fifty patients were subjected to primary optimal debulking surgery, followed by adjuvant combination chemotherapy either cisplatin-cyclophosphamide or paclitaxel-carboplatin with comparable treatment outcome. The other 35 cases were not amenable to optimal surgery. They received primary chemotherapy, either cisplatin-cyclophosphamide or paclitaxel-carboplatin. The overall median duration of response and survival in this subgroup was 12 and 28 months, respectively, which was significantly lower than in those subjected to primary optimal debulking surgery [22 and 35 months, respectively]. However, in the subgroup of patients who received primary chemotherapy [paclitaxel-carboplatin], the median duration of response and survival was significantly higher than those received cisplatin-cyclophosphamide and comparable with those patients subjected to primary debulking surgery and adjuvant chemotherapy. Also, the treatment related toxicity was significantly higher among the patients receiving cisplatin-cyclophosphamide